Rise above: When the right CRO changes everything

In the world of medical device innovation, few phrases generate as much scepticism as “Contract Research Organization.” For many MedTech founders, and even experienced strategics, CROs are often seen as a necessary evil: an unavoidable requirement in clinical development rather than a genuine partner in innovation.

For Jules Bligh, Operations Director, Ascend Clinical Research Organisation, this perception isn’t just familiar, it’s something that needs to change.

Clinical trials are not a box-ticking exercise. They are where technologies prove themselves and where safety, performance, and real patient impact are demonstrated.

The question isn’t whether CROs are necessary. The real question is what happens when a CRO actually adds value? Ascend Clinical was founded to do exactly that.

The CRO: Reimagined

Ascend exists for innovators who think they don’t like CROs. Challenge accepted.

It isn’t because they dislike the concept of clinical research, but because too often the experience has been slow, bureaucratic, and disconnected from the realities of medical device innovation. Sponsors don’t need more problems on their desk. They need solutions.

Medical device companies move quickly. They build, iterate, test, and refine technologies in close collaboration with physicians. Clinical development should support that momentum, not slow it down.

Ascend’s philosophy is simple: Lift you up, not weigh you down.

When sponsors work with Ascend, they aren’t outsourcing clinical operations to a distant vendor. They’re gaining a team that rises with them and shares ownership of the mission to move innovative technologies into real patient care and that’s why we are all here.

Why specialisation matters

One of the biggest challenges in device trials is that many CRO models were originally built around pharmaceuticals. Devices are different.

They’re procedural. They’re operator-dependent. They require training, adoption, and integration into clinical workflows. The success of a device trial often depends not just on the technology itself, but on how physicians interact with it in real-world practice.

That’s why specialization matters. That focus changes everything from study design to site engagement to how monitoring is done. It means understanding what happens in a cath lab, an operating theatre, or a procedural suite—not just what happens on a case report form.

More than speed

Asia-Pacific has already become one of the most attractive regions in the world for medical device trials. The region offers faster recruitment timelines, predictable regulatory pathways, cost effectiveness, and access to world-class clinical investigators capable of generating Tier-1 data. Those advantages are well known.

But what matters even more is how the trial is delivered. At Ascend, meaningful delivery means creating value on both sides of the clinical ecosystem.

For sponsors, it means a CRO that thinks strategically, anticipates problems, and takes operational ownership rather than simply executing tasks. It means transparency, speed, and a team that genuinely understands the pressure and pace of MedTech development.

For investigative sites, it means respect for the reality of clinical practice. Sites are the engine of clinical research, yet too often they experience CROs as an administrative burden. Ascend’s approach flips that dynamic by prioritizing collaboration with investigators and study coordinators, making studies practical to run and ensuring teams feel supported rather than overwhelmed. When sites feel supported, recruitment improves, engagement strengthens, and the quality of data rises.

Support that actually supports

Medical device trials don’t happen behind spreadsheets. They happen in procedure rooms, operating theatres, and clinical settings where physicians are adopting new technology sometimes for the first time. That’s why Ascend integrates medically trained proctors and monitors to ensure procedural insight, and real field support into the way trials are run.

For sponsors, it feels less like working with an external vendor and more like having an experienced extension of your own team on the ground.

Rising together

Our name is not accidental. The idea of ascending reflects the belief that clinical research should elevate everyone involved; the innovators developing technologies, the physicians bringing them into practice, and ultimately the patients who benefit from new treatments.

When sponsors work with Ascend, they’re not just running a trial. They’re partnering with a team that believes clinical development should move innovation forward, not hold it back.

Because when your CRO truly supports both sponsor and site, and when it specializes, collaborates, and delivers real operational value, it stops being a “necessary evil.” It becomes something much, much more powerful. A partner helping MedTech innovation Ascend.